Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Givinostat: an emerging treatment for polycythemia vera.

Expert opinion on investigational drugs - 1 Jun 2020

Chifotides Helen T, Bose Prithviraj, Verstovsek Srdan

Abstract excerpt

INTRODUCTION: Polycythemia vera (PV), a Philadelphia chromosome-negative myeloproliferative neoplasm, is characterized by panmyelosis, pancytosis, and a JAK2 mutation. Patients are at increased risk of thrombohemorrhagic events, and progression to myelofibrosis or acute leukemia. Current treatments include aspirin, phlebotomy, and cytoreductive drugs (most commonly hydroxyurea). Givinostat is a potent, class I/II...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Disease Progression
Share to Histone Deacetylase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydroxyurea

Share to Janus Kinase 2

Share to Mutation

Share to Polycythemia Vera

Source

Open in PubMed Open full text

Identifiers

PMID: 32693648
DOI: 10.1080/13543784.2020.1761323
PMCID: PMC7534842

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Givinostat: an emerging treatment for polycythemia vera.PMID 32693648Read ↗

Polycythemia Vera: Rapid Evidence Review.Semantic proximity Read ↗

How I treat polycythemia vera.Semantic proximity Read ↗

Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

Efficacy of vorinostat in a murine model of polycythemia veraSemantic proximity Read ↗

The advantages and risks of ruxolitinib for the treatment of polycythemia vera.Semantic proximity Read ↗

A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera.Semantic proximity Read ↗

Management of polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.Semantic proximity Read ↗

The treatment of polycythaemia vera: an update in the JAK2 era.Semantic proximity Read ↗

A real-world analysis of polycythemia vera at two comprehensive cancer centers in Cali, Colombia.Semantic proximity Read ↗

Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2(V617F) myeloproliferative neoplasm patients.Semantic proximity Read ↗

Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.